Hospital Pharmacy - June 2020 - 193

Colsoul et al
Chemical stability results showed that lorazepam solutions were stable for 2 days in syringes at 5 ± 3°C and for 4
days in syringes at room temperature while solutions in bottles at both 5 ± 3°C and room temperature were stable for
only 1 day. No sterility test was performed.

Conclusion
Physicochemical stability of lorazepam 167 µg/mL in polypropylene syringes stored at 5 ± 3°C was evaluated to consider the preparation of syringes in advance by a centralized
service. This could contribute to the global management of
treatments by providing geriatric unit with ready-to-use
injectable drugs for relieving patients' anxiety.
This study showed that the physicochemical stability of
lorazepam is limited at 2 days in propylene syringes. Indeed,
lorazepam was not stable due to crystal appearance and a
rapid decrease of lorazepam concentration.
Other conditions (temperature and container) were tested
to improve stability but crystallization occurred in all cases.
Therefore, lorazepam solution at 167 µg/mL in NaCl 0.9%
cannot be prepared in advance, which does not allow a centralized preparation.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect
to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

References
1. Pomara N, Lee SH, Bruno D, et al. Adverse performance
effects of acute lorazepam administration in elderly longterm users: pharmacokinetic and clinical predictors. Prog
Neuropsychopharmacol Biol Psychiatry. 2015;56:129-135.
doi:10.1016/j.pnpbp.2014.08.014.
2. Trissel LA, Pearson SD. Storage of lorazepam in three injectable solutions in polyvinyl chloride and polyolefin bags. Am J
Hosp Pharm. 1994;51(3):368-372.
3. Griffin CE III, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine
pharmacology and central nervous system-mediated effects.
Ochsner J. 2013;13(2):214-223.

193
4. Hecq J-D. Centralized intravenous additive services (CIVAS):
the state of the art in 2010. Ann Pharm Fr. 2011;69(1):30-37.
doi:10.1016/j.pharma.2010.09.002.
5. Hecq J-D. Ten years of European hospital pharmacy history:
centralized intravenous additives services. Eur J Hosp Pharm.
2004;10(6):47.
6. Nahata MC, Morosco RS, Hipple TF. Stability of lorazepam
diluted in bacteriostatic water for injection at two temperatures.
J Clin Pharm Ther. 1993;18(1):69-71.
7. Share MJ, Harrison RD, Folstad J, Fleming RA. Stability of
lorazepam 1 and 2 mg/mL in glass bottles and polypropylene
syringes. Am J Health Syst Pharm. 1998;55(19):2013-2015.
doi:10.1093/ajhp/55.19.2013.
8. Hoey LL, Vance-Bryan K, Clarens DM, Wright DH,
Konstantinides FN, Guay DR. Lorazepam stability in parenteral solutions for continuous intravenous administration. Ann Pharmacother. 1996;30(4):343-346. doi:10.1177/
106002809603000403.
9. Norenberg JP, Achusim LE, Steel TH, Anderson TL. Stability
of lorazepam in 0.9% sodium chloride stored in polyolefin bags. Am J Health Syst Pharm. 2004;61(10):1039-1041.
doi:10.1093/ajhp/61.10.1039.
10. Lugo RA, MacKay M, Rusho WJ. Stability of lorazepam 0.2
mg/mL, 0.5 mg/mL, and 1 mg/mL in polypropylene syringes. J
Pediatr Pharmacol Ther. 2001;6:122-129.
11. Lahlou A, Blanchet B, Carvalho M, Paul M, Astier A.

Mechanically-induced aggregation of the monoclonal antibody
cetuximab. Ann Pharm Fr. 2009;67(5):340-352. doi:10.1016/j.
pharma.2009.05.008.
12. ICH. Validation of analytical procedures: text and methodology Q2(R1). International Conference on Harmonisation of
Technical Requirements for Registration of Pharmaceuticals
for Human Use; November 2005.

13. US Department of Health and Human Services, Food and
Drug Administration, Center for Veterinary Medicine (CVM).
Guidance for Industry Drug Stability Guidelines. 2008.
14. Bardin C, Astier A, Vulto A, et al. Guidelines for the practical stability studies of anticancer drugs: a European consensus
conference. Ann Pharm Fr. 2011;69(4):221-231. doi:10.1016/j.
pharma.2011.07.002.
15. Vellema J, Hunfeld NGM, VandenAkker HE, ter Horst

JH. Avoiding crystallization of lorazepam during infusion.
Eur J Pharm Sci. 2011;44(5):621-626. doi:10.1016/j.ejps.
2011.10.010.
16. Package leaflet: Information for the user. Lorazepam injectable
Temesta 4 mg/ml. http://bijsluiters.fagg-afmps.be/DownloadL
eafletServlet?id=114052. Published February 2017. Accessed
August 21, 2018.

http://bijsluiters.fagg-afmps.be/DownloadLeafletServlet?id=114052 http://bijsluiters.fagg-afmps.be/DownloadLeafletServlet?id=114052

Hospital Pharmacy - June 2020

Table of Contents for the Digital Edition of Hospital Pharmacy - June 2020